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WISP1 IS AN OVEREXPRESSED DRIVER OF GLIOBLASTOMA
Pushan R. Dasgupta, A.B.
Advisory Professor: Giulio F. Draetta, M.D., Ph.D

Despite current multimodal therapies for glioblastoma (GBM) the prognosis
remains very grim. There is a tremendous need to identify new genetic drivers
which can serve as potential therapeutic targets. In order to find new drivers we
leveraged genomic datasets to conduct a context specific in vivo functional
genomic screen of overexpressed and/or amplified genes in GBM. We identified
WISP1, a secreted extracellular matrix protein, to be an overexpressed driver in
GBM. Overexpression of WISP1 was able to drive tumor growth in various in vivo
models. Knockdown of WISP1 with shRNAs resulted in reduced colony formation
in vitro and reduced tumor growth in vivo. Rescue experiments validated that the
shRNAs were on target. Functional characterization of the protein revealed that the
TSP module is necessary for the phenotype. Intriguingly, overexpression of
WISP1 lacking the signal peptide module for secretion resulted in a strong
phenotype. Co-culture and conditioned medium experiments further supported a
secretion independent intracellular role of WISP1 in GBM. Though WISP1 is a
secreted protein we have found some localization in the cytosol. Overall, we have
revealed WISP1 to be a driver of GBM with possible therapeutic potential as a
target. This study has resulted in a paradigm shift in our current understanding of
WISP1 as merely a secreted extracellular matrix protein as we have shown here
x

that it can drive GBM in a non-canonical manner in the cytosol.
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Introduction
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Introduction 1.1: Background on GBM
Close examination of some ancient Egyptian mummies serves as a direct
reminder that humankind has been haunted by a very awful disease for thousands
upon thousands of years. In the 5000 year old Egyptian Edwin Smith Papyrus,
possibly the oldest medical literature available, it is written that this is a grave
disease with no known cure. This disease happens to be cancer. In particular they
were referring to breast cancer in the Edwin Smith Papyrus. One of the most
devastating types of cancer happens to be a form of brain cancer. Glioblastoma
multiforme (GBM) is the most common and most malignant primary central nervous
system tumor (1-5). In fact 16% of all primary and central nervous system
neoplasms are due to glioblastoma (6). GBM is a grade IV tumor with a median
age of presentation of 64 years but the disease can occur at any age (6, 7). It has
an incidence of 3-4 per 100,000/year (1, 4, 5). Roughly 12,000 new patients are
diagnosed a year in the United States alone. The median survival of patients with
GBM is 12.1-14.6 months, and only 3-5% of patients survive longer than 3 years
(8).
Uncontrolled cellular proliferation, widespread invasion throughout the brain,
profound angiogenesis, and a proclivity for necrosis are just some of its key
characteristics (9). Regions of necrosis, microvascular proliferation, abundant
mitoses, and pleiomorphic cells are some of the histological features of GBM (10).
Glioblastoma tumors are also characterized by their resemblance to glia, which are
non-neuronal cells that provide support and protection for neurons in the central
and peripheral nervous systems (7, 11). Intriguingly, though glioblastoma was
2

originally thought to be derived from glial cells, the current experimental evidence
suggests that they may develop from multiple cell types with neural stem cell-like
properties (12, 13). It seems that these cells are in different stages of
differentiation. Moreover, the phenotypic variations can largely be attributed to
molecular alterations in signaling pathways rather than by differences in cell type of
origin (12, 13).
Risk factors and environmental causes of GBM are poorly understood. One
of the few identified risk factors for GBM is exposure to ionizing radiation (14).
There are a few genetic diseases known to increase the risk for glioma such as
Turcot syndrome, Li-Fraumeni syndrome, retinoblastoma, and neurofibromatosis 1
and 2 (14). However, these diseases account for less than 1% of glioma patients
(14).
The size and location of the tumor dictate the presentation of a patient with
GBM (12). Seizures are common presenting symptoms. Symptoms of increased
intracranial pressure like headaches and focal or progressive neurologic deficits
are also common (12). Computed tomography (CT) and magnetic resonance
imaging (MRI) are used for initial diagnostic imaging. It is common for GBMs to
enhance with gadolinium contrast on MRI displaying a ring of enhancement with a
hypointense center of necrosis (12).
Introduction 1.2: Treatment
Before 2005 the standard treatment consisted of surgical resection of the
tumor followed by radiation therapy (RT) alone (15). However, the standard of care
3

for GBM changed after the results of a phase III trial showed that external beam RT
with concomitant temozolamide (TMZ) chemotherapy, an oral alkylating agent, was
more effective than RT alone (15). The addition of TMZ resulted in a median
survival of 14.6 months whereas the median survival for RT alone was 12.1 months
(15).
In 2011 Optune which is a device that delivers tumor-treating fields
(TTFields) was approved by the FDA as monotherapy for recurrent GBM, while in
2015 the FDA approved the use of Optune to be used alongside TMZ for adults
with newly diagnosed supratentorial GBM (12). TTFields deliver low-intensity,
intermediate frequency alternating electric fields that impede the division of cells
(16). Interim analysis data from 315 patients comparing the addition of Optune to
TMZ versus TMZ alone in the adjuvant setting showed that Optune plus TMZ
resulted in superior progression-free survival and overall survival (16).
Unfortunately, despite maximal surgical resection and multimodal therapy around
70% of GBM patients will have disease progression within one year of diagnosis
(15). This nearly inevitable recurrence is a major contributor for why only 3-5% of
patients survive longer than 3 years (8). In terms of the prognosis and poor
response to current treatment, GBM is one of the worst forms of cancer. Thus,
there is a tremendous need to find new therapies for GBM.
Introduction 1.3: The Genomic landscape of GBM and its subtypes
Since cancer is a disease largely driven by genomic aberrations, the hope is
that a better genomic understanding of the disease will allow for the discovery of
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new therapeutic targets. In general, there has been some historical success in a
few types of cancer through the inhibition of pathogenetic cancer alterations (17).
For instance, imatinib, an inhibitor of the Abelson kinase, has led to an enormous
decline in disease mortality for CML (18). Thus, great effort has been placed in
gaining a deeper understanding of the genomic aberrations that lead to GBM.
Multiplatform studies like The Cancer Genome Atlas (TCGA) Research Network
consortium have analyzed the DNA mutations, copy number variations, and mRNA
expressions in tumor tissue samples from hundreds of patients with untreated
primary GBM (19). Somatic alterations in these samples revealed that GBM
consists of deregulation in key components of the p53, RTK (receptor tyrosine
kinase), and RB (retinoblastoma) pathways. In the p53 pathway homozygous
deletion and mutation in TP53 and CDKN2A (ARF) account for most the
aberrations (19). Mutation or amplification in EGFR and mutation or homozygous
deletion in NF1 and PTEN represent most of the alterations in the RTK pathway
(19). Most of the alterations in the RB pathway are: homozygous deletion/mutation
in CDKN2A (p16/INK4A), homozygous deletion in CDKN2B, amplification in CDK4,
and homozygous deletion/mutation in RB1 (19).

This further confirmed years of

experimental evidence implicating these core pathways in GBM and validated the
power of these datasets (9).
GBM can also be categorized in various ways. Some of these distinctions
were made even before the molecular structure of DNA was discovered by Francis
Crick and James Watson let alone a genomic understanding of the disease. In
1940 the German neuropathologist Hans-Joachim Scherer wrote “From a biological
5

and clinical point of view, the secondary glioblastomas developing in astrocytomas
must be distinguished from ‘primary’ glioblastomas. They are probably responsible
for most of the glioblastomas of long clinical duration.” (20). This was a profound
leap at that time in the understanding of GBM as even in 1979 the World Health
Organization did not consider GBM as an astrocytic tumor (20). Primary
glioblastoma is termed de novo glioblastoma and presents as a full-blown tumor
without evidence of a less-malignant precursor (20). On the contrary, secondary
GBM evolves gradually from less malignant astrocytoma like low-grade diffuse
astrocytoma (WHO grade II) or anaplastic astrocytoma (WHO grade III) (20).
Secondary GBM accounts for only 5% of glioblastomas (21). Secondary GBM
tends to occur in younger patients compared to Primary GBM with a 17 year
difference in the mean age (21). Mutations in Isocitrate dehydrogenase 1 and 2
(IDH1 and IDH2) have been shown to be drivers of low-grade gliomas and
secondary GBM (22). Hence IDH mutant gliomas represent a less aggressive
group compared to IDH wild type.
In terms of gene expression-based molecular classification, GBM can be
classified into four subtypes: Proneural, Neural, Mesenchymal, and Classical (22).
The Classical subtype can be characterized by chromosome 7 amplification,
chromosome 10 loss, and a high level of EGFR amplification present in 97% of
classical glioblastomas (22). In the Mesenchymal subtype there is presence of
focal hemizygous deletions of the region containing NF1 at 17q11.2 (22).
Alterations in PDGFRA and point mutations in IDH1 were major features of the
Proneural subtype (22). Likewise most secondary GBMs fall into the Proneural
6

subtype. Expression of neuron markers like NEFL, GABRA1, SYT1, and
SLC12A5 was present in the Neural subtype (22).
Intriguingly, it was found that there is a localization difference in the origin of
these different subtypes. The sub-ventricular zone (SVZ) is a region in the brain
that is adjacent to the lateral wall of the lateral ventricle close to the center of the
brain. Neural stem cells (NSC) and astrocyte precursors are located in the SVZ
(23). NSCs migrate radially and differentiate into various progenitor cells during
development (23). It is thought that genetic aberrations in these cell populations
may be what give rise to GBM (24). It was found that the Proneural and Neural
glioblastoma subtypes tend to occur closer the SVZ while the Mesenchymal and
Classical glioblastoma subtypes tend to develop farther from the SVZ (23).
Beyond finding critical pathways and subtypes of GBM, genomic analysis
has also revealed very interesting characteristics about the biology of the disease.
Telomeres are caps at the end of chromosomes that protect them. Telomeres also
affect the way cells age. Telomerase is an enzyme that elongates telomeres.
Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase.
Genomic analysis of the TCGA datasets found that TERT promoter mutations
correlated with upregulated TERT expression at the RNA level (25). However,
GBM tumors that did not have TERT promoter mutations had ATRX mutations and
did not have increased TERT RNA expression (25). ATRX mutations are
associated with another process that lengthens telomeres called alternative
telomere lengthening (ALT) (26). The genomic data regarding TERT promoter
mutations and ATRX suggest that GBM pathogenesis requires telomere
7

maintenance either through reactivation of telomerase by TERT promoter
mutations increasing the expression of TERT or through ALT resulting from ATRX
mutation (25).

Introduction 1.4: Experimental Models of GBM
With such a complex and difficult disease it is imperative to have powerful
experimental models that properly allow researchers to understand glioblastoma.
Mouse models of glioblastoma are particularly useful in studying disease
progression and tumor pathological progression at the molecular level. Mouse
models also help in understanding fundamental tumor biology like the role of
stroma or the tumor microenvironment. A direct application for mouse models is in
the identification of therapeutic targets.
Xenograft models have been very useful in studying glioblastoma. The most
popular one has been subcutaneous engraftment of human glioblastoma cell lines
to the flank of immunocompromised mice (27). This is very useful in that the tumor
size can be directly followed with a caliper. Due to its utility this has been very
popular in drug development research. However, orthotopic or intracranial
implantation has also become very popular due to its more context-specific
microenvironment for tumor development. The drawback here is that it is difficult to
gauge the growth of the tumors so other more indirect methods like bioluminescent
imaging must be used. The major advantage of xenograft models is that cells of
8

human origin can be used. The discovery and identification of glioblastoma tumor
initiating cells made the use of xenograft models more powerful in terms of its
capacity to model patient tumors. According to the cancer stem cell hypothesis a
unique rare population of cells in the tumor have stem cell-like properties and can
maintain neoplastic clones (28). A CD133+ population was isolated from human
brain tumors that could recapitulate a tumor histologically similar to the patient’s
tumor in mice (28). This was the discovery of the first glioblastoma tumor initiating
cell. Great excitement was witnessed after this finding since it gave the potential to
study the biology of tumors from individual patients. Remarkably, the treatment
response of xenograft tumors derived from tumor initiating cells from patients
mimics the treatment response of the parental GBM (29). This was true for
irradiation, chemotherapy, and targeted therapy of the xenograft tumors (29). The
tumors also had the same genomic characteristics of the specific parental tumor it
was derived from (29). Patient-specific orthotopic GBM xenografts represent a
preclinically valuable translational platform to further understand GBM and its
functional patient to patient variations.
The use of genetically engineered mouse models is another powerful
method to interrogate the biology of glioblastoma. The technology of generating
genetically engineered mouse models allows for many different kinds of
manipulations. In instances where oncogene overexpression or mutation is to be
studied a cell type-specific promoter can be used to drive expression of the gene of
interest (27). In cases where a tumor suppressor is to be studied, knockout mice
can be generated in which a germline deletion removes all or part of the gene of
9

interest (27). One important technique employed in the development of mouse
models is the cre-lox system. In this system the Cre recombinase deletes the
sequences between two loxP sequences (27). The expression of the Cre
recombinase can also be engineered to be expressed by cell type-specific
promoters like the Nestin promoter for expression in neural progenitor cells.
Inducible Cre recombinase is used for temporal control of its expression.
In the case of generating gliomas in mice many have taken advantage of
inactivating the p53 and Rb signaling pathways since these are commonly altered
in the disease (30, 31). In addition to inactivating tumor suppressors others have
found that oncogenic overexpression of V-src can also drive gliomagenesis in mice
(32). Overall there have been numerous mouse models of glioblastoma and
glioma generated involving the inactivation of other tumor suppressor genes like
CDKN2A, Ink4A/Arf, NF1, and PTEN and the activation of other driver genes like
EGFRvIII, RAS, and Akt (33).
Introduction 1.5: Hypothesis and Approach in this Study
Although much research has focused on mutations that drive cancer, it is
also very important to understand genes that can drive cancer simply through
overexpression. There are many different triggers for overexpression from
amplification and epigenetic regulation to even translocation. However, the end
result is the same with overexpression of an oncogenic protein leading to a progrowth, pro-tumor phenotype. There are numerous examples of such genes like:
c-MYC, PLAU, ELMO3, and AIB1 (34-38). It is crucial to discover more of these
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genes as many have the potential to become a therapeutic target.

One approach

to functionally interrogate potential overexpression activated drivers is to perform
gain-of-function cDNA overexpression screens. Several novel drivers for various
forms of cancer have been identified through this approach. For instance, in breast
cancer this approach has led to the discovery of IKBKE and PAK1 as drivers, while
in ovarian cancer it has revealed GAB2 to be a driver (39-41).
In this study we wanted to leverage the current genomic understanding of
GBM in order to discover new drivers. We hypothesized that a context-specific
gain-of-function screen of genes amplified and/or overexpressed in GBM based on
the TCGA datasets would allow us to do this. In order to be context-specific, we
decided to do the screen in an in vivo orthotopic setting using human GBM tumor
initiating cells (GSCs).

Here we report that WISP1 (WNT1 inducible signaling

pathway protein 1), a secreted extracellular matrix protein, is a novel
overexpressed driver of GBM which can exert its pro-oncogenic function noncanonically inside the cell without being secreted.

11

Materials and Methods
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Cell Culture
All cells were cultured at 37 degrees C in a humidified chamber with 5% CO2.
Glioma stem cells (GSCs) were cultured in DMEM/F12 50/50 (Gibco)
supplemented with 1X B27 Supplement (Invitrogen #17504-044), 20ng/mL EGF
(PeproTech), 20ng/mL bFGF (PeproTech), and 1% Pen/Strep. U87MG, LN340,
and LN229 were cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco)
and 1% Pen/Strep (Gibco).
In Vitro Assays
Cell viability was measured using Cell Titer Glo 3D Cell Viability Assay (Promega)
at various time points. 1000 cells were seeded into each well in triplicate in a 6
well plate for the colony formation assay (CFA). After 10-15 days the cells were
fixed with 4% paraformaldehyde and stained with Crystal Violet.
Western blot
Protein lysates were electrophoresed by SDS-Page on 5-15% gradient
polyacrylamide SDS gels. They were transferred onto Nitrocellulose membranes
using a semi-dry transfer apparatus according to the manufacturer’s instructions
(Bio-rad). The membranes were blocked in 5% nonfat milk in TBST (10 mM Tris,
pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 60 minutes. After blocking they were
incubated in primary antibody diluted in 5% nonfat milk in TBST overnight at 4
degrees C. The membranes were then washed three times in TBST for 5 minutes
each and then incubated with a 1:5000 dilution of horseradish peroxidaseconjugated secondary antibodies in 5% nonfat milk in TBST for an hour at room
13

temperature. Finally, the membranes were washed with TBST three times and
band detection was carried out by chemiluminescense reaction followed by film
exposure.
Subcellular Fractionation
Subcellular fractionation was conducted using the Thermo Scientific subcellular
fractionation kit (PI78840) for cultured cells. Cells were trypsinzed and lysed
according to the protocol to obtain cytosolic and membranous fractions.
Immunofluoresence and Confocal Microscopy
Cells were grown in chamber slides and allowed to reach confluence. The media
was removed and the cells were washed in PBS three times for 5 minutes each.
The cells were then fixed in 4% paraformaldehyde for 10 minutes at room
temperature. After another round of washing the cells were permeabilized with
0.5% triton x-100 for 10 minutes at room temperature.

They were washed again

and blocked for one hour in 3% BSA + 1% normal horse serum at room
temperature. After blocking the fixed cells were incubated in primary antibody
diluted in blocking solution overnight at 4 degrees C. The cells were then washed
again as before and incubated in secondary antibody diluted in blocking solution for
1 hour in room temperature. After another round of washing the cells were stained
with DAPI (1:10000 dilution in PBS of 5mg/ml DAPI) for 5 minutes. The cells were
then washed again and treated with DAKO’s antifade mounting medium. The
slides were then coverslipped and allowed to sit in the dark at room temperature.
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Finally the coverslips were sealed with nail hardner. The images were taken on an
FV1000 Olympus Confocal microscope.
ELISA
The human WISP-1/CCN4 DuoSet ELISA kit (DY1627) from R&D systems was
used to measure WISP1 concentrations in the conditioned media and lysate. The
protocol from the kit was followed.
Plasmids
cDNA for all the open reading frames of interest were from the Ultimate ORF
collection (Invitrogen) and transferred by Gateway cloning into the bicistronic vector
pHAGE-EF1α-IRES-GFP. pLKO shRNAs targeting WISP1 expression were
purchased by SIGMA.
Transduction
For the cDNA overexpression cells were transduced with fresh concentrated
lentivirus. After 24 hours the media was changed to fresh media. By 72 hours
after transduction the cells were ready for any downstream application. In the case
of the knockdown experiments, pLKO shRNA from fresh concentrated lentivirus
was used to transduce cells in the presence of 8 µg/ml of polybrene. After 24
hours the media was replaced with fresh media. 48 hours after transduction the
cells were selected with 6µg/ml of puromycin for six days. After selection the cells
were ready for downstream applications like western blotting and/or colony
formation assay.
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Lentivirus Production
HEK293T cells were transfected with a mixture of plasmid and the packagingencoding vectors PMD2.G (Addgene) and pCMVΔR-8.74 (Addgene).
Polyethylenimine (PEI) was used for transfection. Virus-containing supernatant
was collected 72 hours after transfection and filtered through a 0.45µm filter
(Corning). Ultracentrifugation at 23000 rpm for 1.5 hours at 4 degrees C was used
to concentrate the virus. Concentrated virus was used fresh.
Immunohistochemistry
Standard procedures were used to dehydrate and paraffin embed formalin-fixed
tumors. Cut slices were rehydrated and the antigen was unmasked by heating at
95 degrees C for 30 minutes with an antigen unmasking solution (Citra Plus –
Biogenex). After baking and antigen unmasking the tumor samples were incubated
in 3% hydrogen peroxide for 15 minutes. They were then blocked in a 3% BSA,
10% goat serum, and 0.1% triton solution. Finally the samples were incubated in
primary antibody, washed, incubated in HRP-conjugated secondary antibody,
washed, and developed using DAB. Haematoxilin was used to counterstain.
Co-Culture Experiments and Flow Cytometry
Wild type U87MG cells and U87MG cells expressing WISP1_ires_GFP were
transduced to express mCherry_ires_Luciferase. Cells were flow sorted using a
FACSAria Fusion cell sorter to ensure that all cells were expressing their
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respective fluorophore. Cell mixtures for experimental and control groups were 1:1
and were verified by flow cytometry of the parental cells. For the in vivo
experiments 1.5 million cells were injected per mouse and tumors were allowed to
grow for 40 days. Freshly extracted xenograft tumors were dissociated into single
cells using the Tumor dissociation kit from Miltenyi Biotec. The protocol according
to the kit manufacturer was followed. For the in vitro experiments 1000 cells were
seeded into 6 well plates and colonies were allowed to grow for 14 days. The cells
were then trypsinized for subsequent flow cytometric analysis. GFP positive,
mCherry positive, and double positive cells for these experiments were analyzed
using a BD LSRFortessa analyzer. Control cells of each pre-mixture cell type
expressing GFP, mCherry, or both were used for compensation control.
Animal Studies
All animal manipulations were carried out in accordance with institutional, state,
and federal laws under an approved protocol. Mice were anesthetized with
intraperitoneal (IP) injections of ketamine (100mg/kg)/xylazine. These experiments
consisted of 4-6 week old female nude mice purchased from the Department of
Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer
Center (Houston, TX). A guide screw and a multiport microinfusion syringe pump
(Harvard Apparatus, Holliston, MA) were used for the orthotopic intracranial
injections in a method previously described (42, 43). Glioma stem cells (GSCs)
were used for all intracranial injections and 50,000 cells were injected per mouse.
Intracranial tumors were monitored using a Xenogen IVIS-200 imaging system
since they expressed luciferase. For subcutaneous injections cells were injected in
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the flank. For LN340 and LN229 cells were mixed 1:1 with matrigel (Fisher) before
injection. Tumors were measured with a caliper and tumor volume was calculated
using the standard formula: Volume = .5*(l x w^2). For the experiments comparing
GFP and WISP1 in U87MG and LN340, 3 million cells were injected per mouse.
For all other subcutaneous injections 1.5 million cells were injected per mouse.
Genomic DNA extraction and qPCR
Frozen tumors from the screen were cut into small pieces using a sterile scalpel.
The pieces were resuspended in buffer P1 (Qiagen) supplemented with 100µg/ml
RNase A (Promega). GentleMACS M tubes (Miltenyi Biotech) and the
gentleMACS dissociator (Miltenyi Biotech) were used for the dissociation step. The
reference cells did not undergo this dissociation step in the gentleMACS
dissociator. 1/20 volume of SDS (Promega) was added to lyse the cells and they
were incubated at room temperature for 30 minutes. The lysate was passed 20
times through a 22-gauge syringe needle. One volume of Phenol:Chloroform
(Sigma Aldrich) was added to the lysate after which it was vortexed and centrifuged
at 12000 rpm for 12 minutes. The upper phase was separated to a new tube and a
subsequent extraction step was carried out with Chloroform (Sigma Aldrich). Again
the upper phase after centrifugation was transferred to another tube and 0.1
volume of 3M NaCl (Sigma Aldrich) and 0.8 volumes of isopropanol (Fisher
Scientific) were added to precipitate the genomic DNA. The sample was vortexed
and centrifuged at 14000 rpm for 1 hour at 4 degrees C. After centrifugation the
DNA pellet was washed in 70% ethanol (Fisher Scientific) and centrifuged again for
5 minutes at 14000 rpm after vortexing. The ethanol was then removed and the
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DNA pellet was air-dried and dissolved in UltraPure distilled water (Invitrogen).
This solution was put in a shaker at 26 degrees C overnight. NanoDrop 2000
(Thermo Scientific) was used to quantify the DNA. qPCR was done using SYBR
green (Sigma-Aldrich). The program consisted of 2 minutes at 94 degrees C and
40 cycles of 15 seconds at 94 degrees C with 1 minute at 60 degrees C.
Calculations and analysis were performed using the comparative ΔΔCT method.
Computational Analysis
Genes overexpressed and/or amplified in GBM were selected from the TCGA Cell
2013 GBM datasets through cBioPortal (44). These selected genes were used for
the screen. Tissue-specific expression and metadata was obtained from the GTEx
consortium (45). This dataset encompasses 2712 samples across 51 tissue types
from 207 individuals. Each individual additionally had cells cultured from blood and
skin samples, but these were omitted and not included in this analysis. Any
samples procured from the central nervous system, including high cervical spinal
cord, cerebellum, basal nuclei and cortex were classified as “Brain”. All other
samples, including subcutaneaous adipose tissue, tibial artery and nerve, left
ventricular, lung, skeletal muscle, thyroid, skin and blood were classified as “Nonbrain”. Glioma gene expression and clinical metadata was obtained from the
TCGA publication page associated with the recent pan-glioma analysis paper
(46,47). This dataset consists of 486 primary grade II-IV gliomas with available
RNA sequencing-based gene expression, clinical data (histology and grade) and
IDH status. This dataset spans different histological subtypes, including
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astrocytoma (n=116), oligodendroglioma (n=144), oligoastrocytoma (n=93) and
glioblastoma (n=144). Boxplots were plotted using ggplot2 (48).
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Results
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Results 1.1: In Vivo Context-Specific Gain-of-Function Screen Identifies
WISP1 as a Potential Driver in GBM
In order to identify novel genetic drivers of GBM, we started with the
rationale that some of the genes amplified and/or overexpressed in GBM will
represent drivers. Analysis of the GBM TCGA datasets allowed us to produce a list
of amplified and/or overexpressed genes in GBM comprising 74 genes. To find
novel functional drivers among these genes we decided to do a context-specific in
vivo functional genomic gain-of-function screen. We hypothesized that
overexpression of driver genes would reduce the latency of tumor formation. In
order to best appreciate a potential difference in latency, we chose the
glioblastoma tumor initiating cell line GSC 7-11 for its slow 8-9 month latency (Fig
1). In the GSC and GBM lines used in this study we kept in mind the genomic
alterations such as copy number and mutation status (Appendix 1). We
overexpressed our gene(s) of interest using a bicistronic IRES vector in pHAGE
such that GFP would also be expressed along with our gene(s) of interest. The
EF-1α promoter was used to drive constitutive expression. Lentivirus-mediated
transduction was employed to overexpress the gene(s) of interest. In addition to
the 74 genes we included isoforms of some of these genes giving a total of 87
open reading frames (ORFs) for the screen. EGFRvIII was used as the positive
control as it is a known driver of GBM while GFP was used as the negative control
(49). We used a pooled strategy where cells were transduced with roughly 6-7
ORFs per pool. We made sure that the ORFs in each pool were of similar size.

23

24

Figure 1. Flow chart outline depicting the design and
details of the screen.
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There were 12 such pools to cover the 87 ORFs. Each pool consisted of roughly
10 mice. The cells were injected orthotopically into the forebrains of nude mice
and allowed to grow as tumors. Before injection some of the same cells were kept
as parental reference cells. We hypothesized that cells transduced to overexpress
a driver would begin to dominate the population of cells in the tumors with reduced
latency such that qPCR of genomic DNA of the tumor compared to that of the
parental cells would indicate significant fold enrichment for the driver gene. We
used a qPCR strategy where the forward primer was the same for all the ORFs as
it was complementary to a portion of the EF1-α promoter but the reverse primer
was unique to each ORF. For normalization two primers outside the long terminal
repeat (LTR) sequences were used to amplify a portion of the plasmid which
served as the control (Fig 2).
The injected cells were also transduced to express mCherry_ires_Luciferase
which allowed us to image the mice for tumor development using bioluminescent
imaging. As predicted some of the pools had a reduced latency compared to the
GFP control indicating the presence of a potential driver. Among these were pools
1, 2, 9, and 12. Mice in these pools developed tumors faster and displayed
reduced survival (Figure 3). We harvested the tumors from these mice and
extracted the genomic DNA for qPCR analysis. In the analysis we considered any
enrichment of greater than two fold to be indicative of a potential driver. In this
definition there were five potential drivers from the screen: prostate stem cell
antigen (PSCA), Ly6/PLAUR Domain Containing 2 (LYPD2), chromatin
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accessibility complex 1 (CHRAC1), TatD Dnase Domain Containing 1 (TATDN1),
and WNT1 inducible
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Figure 2. A diagram depicting the qPCR strategy used.
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Figure 3. Survival curves for the pools from the
screen that had a reduced latency. LogRank (MantelCox) test shows statistical significance for the survival
of each pool relative to the GFP negative control: Pool
1 (n=9) p=.0005, Pool 2 (n=9) p=.0009, Pool 9 (n=8)
p=.0018, Pool 12 (n=10) p=.001), n=5 for GFP control.
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signaling pathway protein 1 (WISP1) (Fig 4-7). Even though pool 1 had a reduced
latency none of the overexpressed ORFs in pool 1 had a two-fold or greater
enrichment in the qPCR analysis. This is most likely explained by synergistic
effects of that particular combination of genes rather than due to a certain driver
gene(s). Among these five genes we were interested to know which one was the
most promising potential driver. In order to compare these genes for their
relevance in GBM and glioma we analyzed various datasets. Using tissue-specific
expression and metadata from the GTEx consortium we found that all of these
genes except TATDN1 showed significantly lower expression in brain versus nonbrain tissue (Fig 8). We next compared gene expression in TCGA glioma samples
according to glioma grade. For all the genes except LYPD2, expression was
associated with tumor grade but a positive association was found to exist for
CHRAC1 and WISP1. Both of these genes showed higher expression in grade
four tumors relative to grade II-III, and this difference is visually the greatest for
WISP1 (Fig 9).

WISP1 is known to have very little expression in the brain but

based on this analysis we have found that WISP1 is overexpressed in GBM as its
expression is progressively higher in higher grades of glioma with GBM (grade IV)
having the highest level relative to grade III and grade II glioma (50, Fig 9).

IDH

wild type gliomas are more aggressive while IDH mutant gliomas are less
aggressive (51). We therefore wanted to see which of these genes are expressed
higher in IDH wild-type versus IDH mutant tumors. Comparison of gene
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Figure 4. qPCR fold changes for Pool 1 are shown for each ORF relative to the
reference. The mean represents the average fold change for each ORF from 5
tumors derived from the first 5 mice in each pool to be sacrificed. The error bars
represent the standard error of the mean. The ORFs are also specified in
parentheses as either: TRUNC-truncated versions, V-variants, Full-full length
form, C-ORF clones. The “hit” genes with a fold change above 2 are in red while
the rest are in blue.
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Figure 5. qPCR fold changes for Pool 2 are shown for each ORF relative to the
reference. The mean represents the average fold change for each ORF from 5
tumors derived from the first 5 mice in each pool to be sacrificed. The error bars
represent the standard error of the mean. The ORFs are also specified in
parentheses as either: TRUNC-truncated versions, V-variants, Full-full length
form, C-ORF clones. The “hit” genes with a fold change above 2 are in red while
the rest are in blue.
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Figure 6. qPCR fold changes for Pool 9 are shown for each ORF
relative to the reference. The mean represents the average fold
change for each ORF from 5 tumors derived from the first 5 mice in
each pool to be sacrificed. The error bars represent the standard error
of the mean. The ORFs are also specified in parentheses as either:
TRUNC-truncated versions, V-variants, Full-full length form, C-ORF
clones. The “hit” genes with a fold change above 2 are in red while
the rest are in blue.
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Figure 7. qPCR fold changes for Pool 12 are shown for each ORF
relative to the reference. The mean represents the average fold
change for each ORF from 5 tumors derived from the first 5 mice
in each pool to be sacrificed. The error bars represent the
standard error of the mean. The ORFs are also specified in
parentheses as either: TRUNC-truncated versions, V-variants,
Full-full length form, C-ORF clones. The “hit” genes with a fold
change above 2 are in red while the rest are in blue.
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expression in TCGA glioma samples according to IDH status revealed that
expression of all these genes except LYPD2 associated with IDH status. CHRAC1
and WISP1 both showed decreased expression in IDH mutant tumors relative to
IDH wild-type tumors, and this difference was again visually the greatest for WISP1
(Fig 10). We were also interested to see expression differences among the
different Verhaak transcriptional subtypes (22). The expression of all these genes
except LYPD2 and CHRAC1 associated with the tumor subtype (Fig 11). WISP1
showed increased expression in mesenchymal and classical tumors compared to
the neural and proneural subtypes (Fig 11). This is intriguing as the proneural
subtype tends to have a longer survival compared to the other subtypes.
Though the GSC 7-11 line had an amplification in the region containing the
WISP1 gene, we found that the GSC 7-11 line had the lowest protein expression of
WISP1 of any of our GSC lines (Appendix 2). It was even lower than in lines not
harboring an amplification (Appendix 2). Therefore, use of the GSC 7-11 line to
identify WISP1 through an overexpression screen was rationalized. Taken
together, WISP1 demonstrated to be the most promising potential driver and the
most relevant gene among these five in glioma.
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Figure 8. Comparison of gene expression in GTEx tissue
samples (n=2,712, Methods) grouped according to whether the
sample was procured from brain tissue (n=357) or non-brain
tissue (n=2,355). RNA sequencing RPKM values for the five hits
from the preliminary screen are shown. Groups were compared
for each gene individually using a two-sided t-test. N.S. not
significant; * P < 0.05; ** P < 0.001; *** P < 0.0001.
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Figure 9. Comparison of gene expression in TCGA glioma
samples (n=486, Methods) according to glioma grade. RNA
sequencing RPKM values for the five hits from the preliminary
screen are shown. Groups were compared for each gene
individually using a one-way ANOVA. N.S. not significant; * P <
0.05; ** P < 0.001; *** P < 0.0001.
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Figure 10. Comparison of gene expression in TCGA glioma
samples (n=486, Methods) according to IDH status. RNA
sequencing RPKM values for the five hits from the
preliminary screen are shown. Groups were compared for
each gene individually using a two-sided t-test. N.S. not
significant; * P < 0.05; ** P < 0.001; *** P < 0.0001.
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Figure 11. Comparison of gene expression in TCGA glioma
samples (n=486, Methods) according to transcriptional
subtype. RNA sequencing RPKM values for the five hits from
the preliminary screen are shown. Groups were compared for
each gene individually using a one-way ANOVA. N.S. not
significant; * P < 0.05; ** P < 0.001; *** P < 0.0001.
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Results 1.2: WISP1 overexpression drives tumor growth in GBM

We next sought to validate WISP1 as a driver of glioblastoma. Like before,
GSC 7-11 cells were transduced to overexpress WISP1 in the same way but this
time WISP1 was the only ORF. Again EGFRvIII expression and GFP expression
were used as positive and negative controls. The cells were injected orthotopically
again into the forebrains of nude mice and the latency of tumor development was
compared to that of the GFP control. WISP1 overexpression alone was able to
drive tumor growth resulting in a reduced latency (Fig 12). We also conducted this
experiment in GSC 8-11 and found that WISP1 reduced the latency again (Fig 13).
Now that we saw the effect of WISP1 overexpression in this orthotopic model, we
were curious to see the effect in a more tangible subcutaneous model where we
could easily see and assess tumor growth directly. The U87MG cell line was
transduced to overexpress either WISP1_ires_GFP or GFP_ires_GFP and injected
subcutaneously in the flanks of nude mice. The tumors overexpressing WISP1
grew significantly faster resulting in much larger tumors at the same time (Fig 14).
They also had a higher percentage of Ki67 positive cells based on
immunohistochemistry of the tumor tissue (Fig 15). These results indicated that
WISP1 is able to drive tumor growth but we were also curious if WISP1
overexpression could induce tumor formation in a GBM line that does not readily
form tumors subcutaneously. Again we found that WISP1 overexpression resulted
in 40% tumor formation while it was 0% in the GFP expressing control using the
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GBM line LN340 (Fig 16). These tumors were followed for close to 50 weeks but
the results were the same since day 45 after implantation.
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p=.0005 (WISP1 vs GFP)
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Figure 12. Survival curves for mice orthotopically injected
with transduced GSC 7-11 cells. cells n=5 and the reduction
in tumor latency after WISP1 overexpression compared to
GFP control was statistically significant with p=.0005 based
on LogRank (Mantel-Cox) test.
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p=.0018 (WISP1 vs GFP)
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Figure 13. Survival curves for mice orthotopically injected with
transduced GSC 8-11 cells. n=9 (WISP1 group) and n=8 (GFP
group). The reduction in tumor latency after WISP1
overexpression compared to GFP control was statistically
significant with p=.0018 based on LogRank (Mantel-Cox) test.
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p=.0004
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Figure 14. Tumor growth after subcutaneous injection with
U87MG cells transduced to overexpress WISP1 or GFP.
n=10 for each group of mice. The error bars represent the
standard error of the mean. 3 million cells were injected per
mouse. The photo is of the tumors at the last time point of
the experiment. p=.0004 at the last time point based on
two sided t test.
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p=.0001
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Figure 15. Immunohistochemistry of the tumors derived
from the U87MG cells. The Ki67 labeling index was
measured for both groups. The error bars represent
standard deviation. p=.0001 based on two sided t test.
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Figure 16. Percent of tumor formation over time after subcutaneous
injection with LN340 cells transduced to overexpress WISP1 or GFP.
n=10 for each group of mice. 3 million cells were injected per mouse.
Immunohistochemistry of the resulting tumors after WISP1
overexpression (bottom).
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Results 1.3: WISP1 knockdown reduces growth in GBM
We next sought to understand if WISP1 suppression had a pronounced
phenotype as this would be very interesting from a potential therapeutic
perspective. We conducted colony formation assays and knocked down the
expression of WISP1 using two shRNAs targeting the 3’UTR of WISP1 mRNA in
LN340 and LN229. Compared to the non-targeting shRNA control (shNT),
knockdown of WISP1 resulted in fewer colonies in vitro (Fig 17, 18). In order to
confirm that the observed effects were on target, we went ahead to rescue the
impaired ability to form colonies after WISP1 knockdown. Expression of WISP1
cDNA that lacks the 3’UTR targeted by sh70 was able to rescue the impairment in
colony formation induced by WISP1 knockdown in both LN340 and LN229 (Fig 19,
20). Knockdown of WISP1 in the GSC 6-27 line using four shRNAs led to a
reduction in growth as measured by a cell viability assay that measures ATP (Fig
21). Sh50 and sh52 targeted the coding region while sh70 and sh91 targeted the
3’UTR of the endogenous WISP1 mRNA. Photos taken on the last day of the
growth assay also indicated reduced growth (Fig 21).
We next wanted to see if WISP1 knockdown could reduce tumor growth in
vivo. Again we knocked down expression of WISP1 in U87MG cells using the sh91
shRNA. The cells were injected subcutaneously. No tumors resulted after
knockdown of WISP1 while the control non-targeting shRNA (shNT) expressing
tumors grew predictably as U87MG does (Fig 22). These experiments nominate
WISP1 as a potential target of interest for future GBM therapy.
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Figure 17. Colony formation assay after WISP1
knockdown with two different shRNAs in LN340 cells.
Immunoblot is for WISP1 in control and knockdown
lines.
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Figure 18. Colony formation assay after WISP1 knockdown with two
different shRNAs in LN229 cells. Western blot for WISP1 in control
and knockdown lines.
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Figure 19. Rescue experiment showing colony formation assay
in LN340 cells expressing either pHAGE-WISP1_ires_GFP or
pHAGE-GFP_ires_GFP. The cells also expressed either an
shRNA targeting WISP1 (sh70) or a control shRNA (shNT).
Protein expression is shown in the immunoblot for each
condition.
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Figure 20. Rescue experiment showing colony formation assay in
LN229 cells expressing either pHAGE-WISP1_ires_GFP or pHAGEGFP_ires_GFP. The cells also expressed either an shRNA
targeting WISP1 (sh70) or a control shRNA (shNT). Protein
expression is shown in the immunoblot for each condition.
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p= 0.0091 (sh52 vs shNT)
p= 0.0001 (sh50 vs shNT)
p= 0.0001 (sh70 vs shNT)
p= 0.0007 (sh91 vs shNT)
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Figure 21. Growth of GSC 6-27 cells in culture after knockdown of
WISP1. Values are relative cell growth based on CellTiterGlo
measurements of viability over time normalized to day 0. The error
bars represent standard deviation. The pictures were taken on the
last time point. Western blots for WISP1 in control and knockdown
lines are also shown. p= 0.0001 (sh50 vs shNT), p= 0.0091 (sh52 vs
shNT), p= 0.0001 (sh70 vs shNT), p= 0.0007 (sh91 vs shNT)
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Figure 22. Subcutaneous tumor growth after injection with U87MG
cells expressing either control shRNA (shNT) or shRNA targeting
WISP1 (sh91). n=4 for the number of mice in the shNT control group
and n=5 in the sh91 knockdown group. The error bars indicate the
standard error of the mean.
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Results 1.4: Generation of truncated forms of WISP1 lacking specific
modules
WISP1 is a secreted matricellular protein. It is composed of 367 amino
acids and in addition to the signal peptide (SP) module it contains four structural
modules (23). The structural modules are IGFBP, VWC, TSP, and CT. The
IGFBP module is structurally related to the insulin-like growth factor binding domain
while the VWC module comprises the von Willebrand factor type C domain. The
TSP module is homologous to the thrombospondin type I repeat and the CT
module is structurally related to the carboxyl-terminal domain (52). We were
interested in understanding which of these modules are necessary for the tumor
driving phenotype in glioblastoma. In order to tackle this problem, we developed
constructs of WISP1 in pHAGE lacking each of these 5 modules using the
bicistronic vector as before (Fig 23). There is a natural variant of WISP1 which
lacks the VWC module. We used that variant as the delta VWC since it is naturally
occurring. U87MG cells were transduced to overexpress either GFP, EGFRvIII,
WISP1, or one of the WISP1s designed to lack one of the five modules. The
U87MG line was chosen because it gave a very dramatic in vivo difference in
previous experiments allowing us to now use this system to identify portions of
WISP1 that are necessary for the phenotype. We performed western blot analysis
on these cells to confirm the presence of these truncated forms of WISP1 (Fig 24).
Since the CT module overlaps with the epitope for the WISP1 antibody we had to
use another WISP1 antibody whose epitope overlaps with the VWC module
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instead. This allowed us to detect the CT module (Fig 24). We also sequence
confirmed expression of the respective truncated form of WISP1 expressed in each
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Figure 23. Diagram depicting the truncated
forms of WISP1 made for these experiments.
The in vivo growth promoting activity found
here (Figure 5) is also indicated for each
truncated form.
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Figure 24. Immunoblots from lysates of U87MG cells
expressing each truncated form and the controls (GFP,
EGFRvIII, WISP1). Two different antibodies were used since
the ΔCT WISP1 is not picked up by the antibody that
recognizes an epitope from amino acids 311-367 (sc-25441)
while the ΔVWC WISP1 is not picked up by the antibody that
recognizes an epitope from amino acids 135-230 (ab155654).
An immunoblot membrane using the same antibody against
WISP1 used for the ELISA experiments (1627-WS) confirms
that the antibody recognizes all the truncated forms except for
ΔCT WISP1.
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Figure 25. An immunoblot membrane using the same antibody
against WISP1 used for the ELISA experiments (1627-WS) confirms
that the antibody recognizes all the truncated forms except for ΔCT
WISP1.
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transduced line. The SP module is a tag that targets a protein for secretion. The
delta SP WISP1 should thus not be secreted. ELISA was performed on the media
of each of these respective cell lines expressing either a truncated form of WISP1,
wild type WISP1, GFP, or EGFRvIII. The particular antibody used in this ELISA
does not detect the delta CT WISP1 so we could not measure the concentration of
delta CT WISP1 in the media (Fig 25). We found that the wild type WISP1, delta
VWC WISP1, and delta IGFBP WISP1 had high concentrations in the media of
their respective cells (Fig 26). The concentration of delta SP WISP1 and delta TSP
WISP1 in the media were comparable to that of endogenous WISP1 in the media
of GFP and EGFRvIII expressing cells. However, delta SP WISP1 and delta TSP
WISP1 were detectable by immunoblotting when using the same antibody that was
used for the ELISA. This indicated that delta SP WISP1 and delta TSP WISP1 are
not secreted (Fig 25, 26). We wanted to further confirm that these truncated forms
of WISP1 are truly not secreted so we performed ELISA on the cell lysate and the
cell media using the same protein concentration for both. The concentration of
WISP1 in the media of delta SP WISP1 and delta TSP WISP1 overexpressing cells
matched that of the endogenous protein in the media of control cells expressing
GFP or EGFRvIII. However, higher levels of delta SP WISP1 and delta TSP
WISP1 were detected in the lysate as would be predicted (Fig 27, 28). This further
confirmed that delta SP WISP1 and delta TSP WISP1 were not present in the
media proving that they were indeed not secreted.
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Figure 26. ELISA for WISP1 of media from the cells
expressing the truncated forms of WISP1 and the controls
(GFP, EGFRvIII, WISP1)
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Figure 27. Media are from the same number of
cells in the same volume of media for the same
amount of time. ELISA for WISP1 comparing the
same amount of total protein from cell lysate and
conditioned media for cells expressing either GFP,
EGFRvIII, or ΔSP WISP1
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Figure 28. ELISA for WISP1 comparing the same
amount of total protein from cell lysate and
conditioned media for cells expressing either GFP,
EGFRvIII, or ΔTSP WISP1

89

Results 1.5: Structural functional analysis indicates that non-secreted ΔSP
WISP1 is able to drive growth while ΔTSP WISP1 fails to produce any tumors
in vivo.
We then injected these cells subcutaneously into the flanks of nude mice.
WISP1 is known to function as a secreted protein. However, contrary to
conventional wisdom, expression of the delta SP WISP1 was able to drive tumor
growth even better than any other form of WISP1 (Fig 29-32). Intriguingly,
expression of the delta TSP WISP1 resulted in the formation of no tumors (Fig 30).
Expression of the rest of the truncated forms of WISP1 including overexpression of
the wild type form gave a similar phenotype (Fig 29-32). We repeated this in vivo
experiment again and got the same exact results. We performed western blots on
the protein extracted from these tumors and confirmed the presence of the
truncated forms of WISP1 (Fig 33). These results indicate that WISP1 is able to
drive tumor growth inside the cell without being secreted and that the TSP module
is necessary for the phenotype.
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Figure 29. Subcutaneous tumor growth after injection with
U87MG cells expressing each truncated form of WISP1 and the
controls (GFP, EGFRvIII, WISP1).. Here the GFP and EGFRvIII
control groups are shown. n=5 for the number of mice in each
group. Each line indicates the growth of an individual mouse.
The color of the line indicates the group of the mouse which is
indicated in the legend on the right. 1.5 million cells were
injected per mouse.
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p= 0.0322
WISP1 vs GFP
p= 0.0133
TSP vs GFP
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Figure 30. Subcutaneous tumor growth after injection with
U87MG cells expressing each truncated form of WISP1 and the
controls (GFP, EGFRvIII, WISP1).. Here the WISP1 and ΔTSP
control groups are shown. n=5 for the number of mice in each
group. Each line indicates the growth of an individual mouse. The
color of the line indicates the group of the mouse which is indicated
in the legend on the right. 1.5 million cells were injected per mouse.
p= 0.0322 (WISP1 vs GFP); p= 0.0133 (TSP vs GFP). Statistics are
based on two tailed t test of the measurements from the last time
point.
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p= 0.0272
ΔSP vs GFP
p= 0.0125
ΔCT vs GFP
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Figure 31. Subcutaneous tumor growth after injection with
U87MG cells expressing each truncated form of WISP1 and the
controls (GFP, EGFRvIII, WISP1).. Here the ΔCT and ΔSP control
groups are shown. n=5 for the number of mice in each group.
Each line indicates the growth of an individual mouse. The color of
the line indicates the group of the mouse which is indicated in the
legend on the right. 1.5 million cells were injected per mouse. p=
0.0272 (ΔSP vs GFP) ; p= 0.0125 (ΔCT vs GFP). Statistics are
based on two tailed t test of the measurements from the last time
point.
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p=0.0342
ΔVWC vs GFP
p=0.0226
ΔIGFBP vs GFP
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Figure 32. Subcutaneous tumor growth after injection with
U87MG cells expressing each truncated form of WISP1 and the
controls (GFP, EGFRvIII, WISP1). Here the ΔVWC and ΔIGFBP
control groups are shown. n=5 for the number of mice in each
group. Each line indicates the growth of an individual mouse. The
color of the line indicates the group of the mouse which is indicated
in the legend on the right. 1.5 million cells were injected per mouse.
p= 0.0342 (ΔVWC vs GFP); p= 0.0226 (ΔIGFBP vs GFP). Statistics
are based on two tailed t test of the measurements from the last
time point.
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Figure 33. Immunoblots from lysates of the resulting U87MG
subcutaneous tumors expressing each truncated form and the
controls (GFP, EGFRvIII, WISP1). Again two different antibodies
were used since the ΔCT WISP1 is not picked up by the antibody
that recognizes an epitope from amino acids 311-367 (sc-25441)
while the ΔVWC WISP1 is not picked up by the antibody that
recognizes an epitope from amino acids 135-230 (ab155654). .
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Results 1.6: Secreted WISP1 fails to drive growth in GBM
We were interested in understanding whether WISP1 drives tumor growth in
a novel secretion independent fashion. In order to do this we needed to assess
whether the secreted WISP1 is able to act as a driver. To investigate this we
developed three cell lines for co-culture experiments. Using U87MG we developed
a line expressing mCherry_ires_Luciferase, a line expressing both
mCherry_ires_Luciferase and WISP1_ires_GFP, and a line expressing only
WISP1_ires_GFP. The line overexpressing WISP1 and expressing mCherry was
made from the same cells that were only expressing WISP1_ires_GFP to ensure
that they overexpressed WISP1 at the same level. These three lines were flow
sorted to make sure that all the cells either express GFP, mCherry, or both (Fig
34). The line expressing only WISP1_ires_GFP was mixed with either the line
expressing both WISP1_ires_GFP and mCherry_ires_Luciferase or the one
expressing only mCherry_ires_ Luciferase. We mixed these cells in a 1:1 ratio and
then confirmed the proportions by flow cytometry analysis. This generated two
mixtures with the experimental mixture as a combination of green and red cells
(WISP1_ires_GFP expressing cells and mCherry_ires_Luciferase expressing cells)
and the control mixture as a combination of green and double positive cells
(WISP1_ires_GFP expressing cells and WISP1_ires_GFP +
mCherry_ires_Luciferase expressing cells). These cells were then either seeded
for colony formation assay in vitro or injected subcutaneously in vivo (Fig 34). Our
hypothesis behind this experiment was that if WISP1 drives growth through
secretion then the line only expressing mCherry_ires_Luciferase should be
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Figure 34. Schematic diagram describing the co-culture
experimental design..
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Figure 35. In vitro co-culture results after colony formation assay
showing the ratio of green cells to red cells in experimental groups
and the ratio of green only cells to double positive cells in control
groups. Each graph A-C represents cells from two different colony
formation assay wells for each condition (experimental or control).
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stimulated by the WISP1 secreted by the WISP1_ires_GFP expressing cells in the
mixture. If this is the case, then the final proportions of GFP+ cells after colony
formation or tumor formation should be the same in both the experimental mixture
and the control mixture. If the secreted WISP1 is not able to induce growth then
one would expect the proportion of GFP+ cells to be higher in the experimental
mixture compared to the control mixture. This would indicate that the WISP1 is
acting within the cell to promote growth. After development of colonies the cells
were trypsinized for flow cytometry analysis. Likewise after tumor development the
tumors were dissociated into single cells for flow cytometry analysis. The ratio of
cells that are only GFP+ to mCherry+ cells was much higher in the experimental
groups compared to that of the controls (Fig 35A-C). Each graph represents cells
from two wells of a 6 well plate after 2 weeks of colony formation. It seems that
there is a tendency for the mCherry_ires_Luciferase expressing cells to grow faster
based on the shift towards mCherry+ cells in the control mixture (Fig 35A-C).
However, the WISP1_ires_GFP expressing cells were still able to overcome that
and dominate the experimental mixture. The push towards mCherry+ cells was
even stronger in vivo but still the tumors derived from the experimental mixture had
an even higher ratio of only GFP+ cells to mcherry+ cells compared to that of
controls ( Fig 36A-C). Each graph represents the results of a single tumor. These
results support the notion that WISP1 does not drive growth through secretion but
rather drives growth inside the cell.
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Figure 36 In vivo co-culture results after tumor development
showing the ratio of green cells to red cells in experimental groups
and the ratio of green only cells to double positive cells in control
groups. Each graph A-C represents cells from a tumor for each
condition (experimental or control).
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Results 1.7: There is ectopic expression of endogenous WISP1 in the cytosol
in GBM
Our next interest was to gain a deeper understanding of WISP1’s
localization within the cell. Since WISP1 is a secreted protein we expected to be
able to find it possibly in the endoplasmic reticulum (ER), Golgi, or endosomes.
We performed immunofluorescence and confocal microscopy of U87MG cells
using EEA1 as an endosomal marker, AE6 as a Golgi marker, and Calreticulin as
an ER marker. We did not see localization in the Golgi or endosomes (Fig 37-38).
However, we did find that WISP1 co-localized with Calreticulin indicating
localization in the ER (Fig 39). We interpret this to mean that there is a much more
substantial portion of WISP1 in the ER than possibly in the Golgi or endosomes.
We also noticed that WISP1 did not seem to be present in the nucleus (Fig 37-41).
We were intrigued by the functional studies demonstrating that expression of the
delta SP WISP1 could drive tumor growth. Normally translation begins in the
cytosol and the signal peptide directs the protein to the ER to join in the secretory
pathway (53). However, the delta SP WISP1 should not be directed to the ER
since it lacks the signal peptide and instead should probably remain in the cytosol.
The presence of delta SP WISP1 in the cytosol would implicate the cytosol as an
important area for WISP1 function in GBM. For the cytosol to be relevant
endogenous WISP1 would also need to be present there. To investigate this we
conducted immunofluorescence and confocal microscopy of both U87MG and
U87MG expressing the delta SP WISP1. Alpha tubulin was used as the cytosolic
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marker. Though the antibody against WISP1 will detect both endogenous and
delta SP WISP1 we still wanted to compare the localization. Endogenous WISP1
was indeed found to be present in the cytosol and delta SP WISP1 was in the
cytosol as well (Fig 40-42).
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Figure 37 Immunofluorescence of U87MG
cells for DAPI, WISP1, and the endosomal
marker EEA1. Images were captured by
an FV1000 Olympus Confocal microscope.
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Figure 38 Immunofluorescence of U87MG cells for DAPI, WISP1,
and the golgi marker AE6. Images were captured by an FV1000
Olympus Confocal microscope.
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Figure 39 Immunofluorescence of U87MG cells for DAPI, WISP1,
and the endoplasmic reticulum marker Calreticulin. Images were
captured by an FV1000 Olympus Confocal microscope.
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Figure 40. Immunofluorescence of U87MG cells for DAPI, WISP1,
and the cytosolic marker α-Tubulin. Images were captured by an
FV1000 Olympus Confocal microscope.
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Figure 41. Immunofluorescence of U87MG cells expressing ΔSP
WISP1 for DAPI, WISP1, and the cytosolic marker α-Tubulin.
Images were captured by an FV1000 Olympus Confocal
microscope.
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Figure 42. Immunoblot of lysate from U87MG cells (left) and
U87MG cells expressing ΔSP WISP1 (right) that was fractionated
into cytosolic (C) and membranous (M) fractions. Unfractionated
whole lysate (WL) was also immunoblotted.
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The delta SP WISP1 seemed to be more dispersed throughout the cytoplasm while
the major concentration of the endogenous WISP1 seemed to be perinuclear
where the ER is located. We also utilized another method to investigate the
localization. We performed fractionation and immunoblotting to more precisely see
the various levels of the protein in different subcellular fractions of the lysate. We
compared the levels of WISP1 and delta SP WISP1 in the whole lysate, cytosolic
fraction, and the membranous fraction which comprises organelles like the ER.
The ER marker Calnexin was used as a control for the membranous fraction while
alpha-Tubulin was used as a control for the cytosolic fraction. The Delta SP
WISP1 appeared as a band just under the endogenous WISP1 in the immunoblot
(Fig 42). We found that the endogenous WISP1 is primarily in the membranous
fraction which makes sense as it is secreted and should be targeted to the ER.
Intriguingly, there was also a portion of the endogenous WISP1 in the cytosol
confirming the immunofluorescence results (Fig 42). This further confirmed that
the cytosol is relevant since endogenous WISP1 is present there. As predicted the
delta SP WISP1 was primarily in the cytosolic fraction while a small portion of it
was seen in the ER (Fig 42). These results make it quite plausible that WISP1
functions in the cytosol as a driver in GBM.
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WISP1 functions in a non-canonical manner in the cytosol
An interesting question is whether cytosolic WISP1 functions through a
different pathway than its secreted canonical counterpart. Secreted WISP1 is
known to activate Akt by inducing its phosphorylation. The RTK/RAS/PI-3K
pathway which encompasses Akt is an important altered pathway in GBM.
Conventional thought would have implicated activation of Akt as the reason behind
WISP1’s activity in GBM. Astonishingly, though we find that WISP1
overexpression induces phosphorylation of Akt in GBM which is consistent with its
known function in other cell types, overexpression of the delta SP form of WISP1
does not activate Akt (Fig 43). This supports the possibility that WISP1 drives
growth through a non-canonical pathway inside the cell in GBM. It is interesting
that the phenotype of overexpression of the delta SP form of WISP1 was even
more robust than that of wild type WISP1 without such Akt activation. Whatever
WISP1 is doing in the cytosol must be even more oncogenic than the Akt activation
induced by secreted WISP1.
To look for downstream changes induced by WISP1 and delta SP WISP1
we conducted an RPPA of the lysates from tumors derived from U87MG cells
transduced with either GFP_ires_GFP, WISP_ires_GFP, or delta SP
WISP1_ires_GFP. A decrease in Merlin (coded by the NF2 gene) was a very
interesting observation (Fig 44). Merlin is a cytoskeletal protein coded by the NF2
gene. It regulates several signaling pathways controlling cell shape, cell growth,
and cell adhesion. Intriguingly, Merlin is also a known tumor suppressor in GBM
(54, 55). Overexpression of NF2 in U87MG cells was found to reduce tumor
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growth while knockdown of NF2 in U251 was found to increase tumor growth (55).
Mutations in NF2 also lead to neurofibromatosis type II which leads to an increased
risk for glioma and glioblastoma. We validated the RPPA result by western blotting
and found that Merlin was lower after WISP1 overexpression compared to the GFP
control (Fig 45). Consistently, expression of delta SP WISP1 resulted in even
lower levels of Merlin as compared to WISP1 overexpression (Fig 45). These
results are very interesting as they support a possibility that cytosolic WISP1
reduces Merlin leading to greater tumor growth. This could be one of the ways in
which WISP1 works as a driver in GBM.
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Figure 43. Immunoblot for pAkt (S473) and total Akt of lysates
from tumors derived from U87MG cells expressing either GFP,
WISP1, or ΔSP WISP1.

131

132

Figure 44. RPPA heatmap of lysates from tumors derived from
U87MG cells expressing either GFP, WISP1, or ΔSP WISP1. The
heatmap shows the differences in Merlin (NF2)
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Figure 45. Immunoblot for Merlin (NF2) of lysates from tumors
derived from U87MG cells expressing either GFP, WISP1, or ΔSP
WISP1.
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Discussion

136

Despite the current multimodal treatment for GBM, there is a tremendous
need for new effective therapies. The current genomic understanding of the
disease opens up new avenues to find unknown drivers of GBM. Here we have
leveraged the TCGA datasets to conduct a functional genomic screen of “highpriority” genes that are overexpressed and/or amplified in GBM. In order to be
context-specific, the screen was performed in vivo using a human glioma stem cell
orthotopic mouse model. WISP1 emerged as the most relevant and intriguing
gene “hit” from the screen. Based on available datasets we found that WISP1 is
expressed at low levels in the brain but is overexpressed in glioblastoma. The
expression was found to increase with increasing grade of glioma. This implicates
WISP1 in the development of the disease. Furthermore, we found that the more
aggressive IDH wild type forms of glioma had higher levels of WISP1 expression.
Consistently, even less aggressive subtypes of glioma had a lower expression level
of WISP1. Therefore, we chose to investigate WISP1 further.
Until now the role of WISP1 in glioblastoma had been unknown. We found
that overexpression of WISP1 is able to drive tumor growth. WISP1
overexpression was able to reduce the latency of tumor formation in orthotopic
models using GSCs. Likewise in subcutaneous xenograft models using GBM lines,
overexpression led to faster tumor growth. In one line that does not readily form
tumors, overexpression of WISP1 was able to induce tumor formation. This
demonstrates that WISP1 is able to drive tumor growth and formation in GBM.
Intriguingly, based on the datasets we found that the level of WISP1 is low in the
brain relative to its expression in other tissues. However, the increase in WISP1
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expression in glioma and its progressive increase in higher grades of glioma
suggest that WISP1 plays a functional role in making the tumors more aggressive.
This is further supported by the functional evidence we show demonstrating
WISP1’s ability to drive tumor growth. Together, this points to WISP1 as a newly
discovered overexpressed driver of GBM.
Understanding genetic drivers of a disease are important for potential
therapy. We conducted knockdown studies to explore the potential therapeutic
potential of WISP1 as a driver. Knockdown of WISP1 reduced colony formation in
vitro and slowed down tumor growth in vivo. We can attribute these effects to that
of genetic knockdown rather than to off-target effects of the shRNA based on our
rescue experiments. These studies not only support WISP1 as a driver with
potential therapeutic application in GBM but also substantiate its role in driving the
disease.
WISP1 is a secreted extracellular matrix protein and belongs to the CCN
protein family (56). It has no specific identified receptor but most evidence points
towards interaction with integrins as its primary means of activity (57). WISP1 has
been shown to physically interact with the α5β1 integrin with a functional role in
osteogenic bone marrow stromal cells (58). Other studies have found evidence
supporting that WISP1 functions through the αVβ5 integrin (59, 60). Many have
studied the effects of WISP1 on Akt since integrins are known to be able to signal
downstream to targets like Akt (61-63). Extracellular WISP1 has been found to be
able to activate Akt leading to greater phospho-Akt (64, 65). WISP1 induced
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activation of Akt has a functional role. For instance, one study found that it results
in myocyte hypertrophy (65).
We were interested in functionally characterizing the WISP1 protein in GBM.
Structurally, the protein is composed of 5 modules: SP (signal peptide), IGFBP,
VWC, TSP, and CT (55). The signal peptide is a tag that tells the cell that a protein
is destined for secretion. If a protein does not have the signal peptide then
translation of the protein remains in the cytosol. However, if a protein has a signal
peptide then it locates to the ER to embark onto the secretory pathway. The signal
peptide is then cleaved so the secreted protein does not have the signal peptide.
Strikingly, we found that overexpression of WISP1 lacking the signal peptide
module was able to result in a strong growth promoting phenotype. This is
interesting based on the current understanding of WISP1 since it is a secreted
protein and it is thought to function extracellularly while the delta SP form of WISP1
is able to drive growth intracellularly. We also found that the TSP module is
necessary for the phenotype. This raises a possibility that the TSP module may
have an essential function inside the cell to drive GBM. It is surprising that
overexpression of the delta TSP form of WISP1 prevented the formation of any
tumors. We speculate that this could be due to a dominant negative effect where
the delta TSP form of WISP1 prevents the wildtype WISP1 to function. One
possibility is that the TSP module is involved in mediating a crucial protein-protein
interaction that is necessary for the phenotype. Another possibility is that the lack
of the TSP module alters the tertiary structure of the protein preventing it from
functioning.
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The ability of the delta SP form of WISP1 to drive growth sparked our
interest in understanding if the phenotype is secretion independent. The results of
our in vitro and in vivo co-culture experiments indicate that secreted WISP1 is not
able to drive growth. If WISP1 drove growth through secretion then we would
expect that the ratio of green cells to red cells in the experimental group would be
the same as that of the ratio of green cells to double positive (GFP+ and
mCherry+) cells in the control group. This is because the green and red cells in the
experimental group should be exposed to the same secreted WISP1. If WISP1
only acts through secretion then both populations of green cells and red cells
should be stimulated similarly. As an alternative method to test the same
hypothesis we tried to use conditioned medium to rescue colony formation after
WISP1 knockdown. Conditioned medium failed to rescue, while only genetic
expression of WISP1 cDNA was able to rescue colony formation. Together, these
experiments support an alternative means of WISP1 activity in GBM where it
functions inside the cell rather than through secretion.
A key question that next emerged was whether intracellular WISP1 was
biologically relevant. In order to better understand if intracellular WISP1 is
biologically relevant we engaged ourselves to learn about its localization inside the
cell in GBM. We found that WISP1 naturally can be found in the ER and the
cytoplasm. From our fractionation experiments it became clear that though most of
the WISP1 in a cell is in the membranous fraction like in the ER there is still a
portion of it in the cytosol. Whereas, the delta SP form of WISP1 is mostly in the
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cytosol with less in the membranous fraction. This is consistent with what should
happen when the signal peptide is not present.
The notion that WISP1 functions intracellularly in the cytosol even though it
is a secreted extracellular matrix protein represents a paradigm shift in our
understanding of WISP1. Gradually some extracellular matrix proteins like
osteopontin or fibulin-1D are starting to be reported to have non-canonical
intracellular locations and functions like what we find here for WISP1 (66). This is
a very intriguing concept from many standpoints. From an evolutionary perspective
it is quite puzzling that a protein evolved to be secreted and function in the
extracellular matrix will have such an impactful role in the cytosol. Another key
question is why a protein will localize ectopically to the cytosol when it should be
secreted. One potential answer to this that we believe may apply to WISP1 is
alternative translation initiation. Just as alternative splicing leads to a multiplicity of
functional protein isoforms, alternative translation initiation does the same. It can
occur due to leaky scanning by 40S ribosomal subunits which miss the proper AUG
translation initiation site and end up scanning farther in the 3’-direction until
recognizing a downstream AUG codon as a translation initiation site (67). Thus,
part of the protein does not get translated leading to a truncated isoform. It is
thought that some properties of the mRNA can influence the AUG recognition. For
instance, the stability of the secondary structure can change the pace of the 40S
during translation, leading to leakiness and translation initiation from an alternative
site (68). Osteopontin is an example of such a protein that is secreted but due to
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alternative translation initiation an isoform of it results lacking the signal peptide
(69). Remarkably, it then has a different function inside the cell.
We believe that alternative translation initiation is a possibility for WISP1 in
GBM. In the mRNA transcript of WISP1 we intriguingly found an in-frame AUG
codon after the first 27 codons. If translation initiates from this downstream AUG
site then it would result in a truncated form of WISP1 lacking the signal peptide. In
our fractionation experiments we noticed two bands for WISP1 in the whole lysate
of U87MG. There was a strong band and a slightly lower molecular weight light
band. Surprisingly, it is this light band that remains in the cytosolic fraction while in
the membranous fraction we only see the strong higher molecular weight band. It
is quite conceivable that the slightly lower molecular weight WISP1 present in the
cytosolic fraction possibly represents a truncated isoform lacking the signal peptide
due to alternative translation initiation.
The downregulation of Merlin by cytosolic WISP1 was a very interesting
observation. Merlin is a known tumor suppressor in GBM which makes this a
plausible mechanism through which WISP1 may be functioning. Clinically patients
with mutant Merlin are at much greater risk of developing GBM. Based on the lack
of Akt activation by the delta SP WISP1 it seems that WISP1 is involved in a
different pattern of signaling inside the cell which is very effective in driving GBM
growth. WISP1 may be functioning through Merlin suppression to exert its
oncogenic activity in glioblastoma. Together, this suggests a model where WISP1
functions through an alternative non-canonical pathway of signaling to promote
glioblastoma growth (Fig 46).
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Figure 46. Hypothetical model of one possibility for what WISP1
may be doing to drive GBM
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Future Directions
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This work opens up numerous possibilities and many new questions. The
first striking question that emerges is how exactly WISP1 is able to drive GBM.
This is even more interesting in light of the new found understanding that WISP1
can work intracellularly in GBM. It is quite intriguing that a protein made to work
outside the cell could elicit such a powerful function inside the cell. One hypothesis
I would propose is that WISP1 functions through binding another protein. This
seems quite plausible based on the data I got after expression of the delta TSP
WISP1. The lack of this module resulted in what looks like a dominant negative
effect. It was a striking result to see the lack of any tumor development after
expression of the delta TSP WISP1. This is a similar phenotype as WISP1
knockdown. This makes me think that the delta TSP WISP1 obstructs the wild type
WISP1 from interacting with its partner. For this to be true it also means that the
TSP module must be the binding site. More research is needed to find what this
TSP module binds to. Again another possibility is that the lack of the TSP module
results in important changes in the tertiary structure of the protein rendering it nonfunctional. This possibility should also be investigated.
The result that Merlin goes down after WISP1 overexpression and after
expression of delta SP WISP1 also gives insight into a potential mechanism.
Perhaps the binding of WISP1 to its interacting partner in the cytosol leads to
Merlin downregulation. It would be very interesting if the change in the level of
Merlin is the major contributor towards WISP1’s ability to drive GBM. This could
potentially open up greater interest and attention towards understanding the role of
Merlin in GBM. Most of the research with Merlin has dealt with its primary role in
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Neurofibromatosis type II. A deeper understanding of Merlin in GBM could
potentially also have translational impact in the future.
Another interesting question that comes to my mind is why WISP1 is
overexpressed in GBM in the first place. There could be an activating event that
leads to WISP1 overexpression. Since WISP1 is normally so low in the brain, I
believe that a primary culprit in GBM is whatever is causing the overexpression in
the first place. More research in finding the reason behind its overexpression is
necessary. There could be an epigenetic reason for this, as one possibility for
WISP1 upregulation could be demethylation of the WISP1 promoter. One study
found decreased DNA methylation levels in the WISP1 promoter in primary oral
squamous cell carcinoma of patients with lymph node metastases (70). This
decreased DNA methylation was also found to correlate with increased WISP1
expression (70). It could be that there is a demethylation in the WISP1 promoter in
GBM which leads to the upregulation of WISP1 expression.
Though the overexpression of WISP1 may be due to another factor, I still
believe that WISP1 itself may prove to be a very interesting therapeutic target. The
results of the knockdown experiments I got reveal that potentially inhibiting WISP1
should lead to a reduction in GBM growth. In this regard, at least from a
translational standpoint, it is more important to understand how to inhibit WISP1 in
the cytosol rather than understand why it is overexpressed in GBM.
As I mentioned in the Discussion section, I believe that the ectopic
expression of WISP1 in the cytosol may be due to alternative translation initiation.
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I am really curious as to why a portion of WISP1 ends up in the cytosol. This is
another interesting area of future research from a more fundamental molecular
biology standpoint. A deeper understanding of this will also generate a greater
appreciation for the diversity and complexity that can be generated by a relatively
limited number of human genes.
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Conclusion
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My dissertation work has revealed WISP1 to be a driver of GBM with
possible therapeutic potential as a target. Our current understanding of WISP1 as
a secreted extracellular matrix protein has changed as I have shown here that it
can drive GBM in the cytosol most likely through a non-canonical pathway. This
has opened up new avenues for investigation both in understanding further what
specifically WISP1 is doing in the cytosol to drive GBM and in exploring this unique
paradoxical class of secreted extracellular matrix proteins that have important noncanonical roles inside the cell.
Just like the ancient Egyptians who wrote over 5 millennia ago that breast
cancer has no known cure, today we must say the same for GBM. However,
breast cancer currently has a far, far better prognosis than ever before imagined in
those days. It took the combined effort of countless scientists from countless fields
over this vast stretch of time to bring us here today. One scientific advance must
base itself on another in this endless journey towards the discovery of greater
scientific truth. Perhaps one day we will look back at us today just as we can now
look back at the time of the ancient Egyptians and think to ourselves how far we
have come in a world where glioblastoma is no longer such a devastating disease.
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Appendix 1: Genomic background of the GSC and
GBM lines showing the mutation and copy number
states.
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Appendix 2: Immunoblot of various GSC lines.
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